about
Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma.Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs.P38 activation mediates amyloid-beta cytotoxicity.Autologous Stem Cell Transplantation After Second Line Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma.How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT.Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.Melphalan-Based Reduced Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemiaTherapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to acute lymphoblastic leukemia, but outcomes are comparable in transplanted patientsMIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimenAllogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.The role of transplant in multiple myelomaOutcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaOutcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantationLong-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphomaCharacteristics and Trends of Adult Acute Lymphoblastic Leukemia in a Large, Public Safety-Net HospitalPulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosisPost-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria ClonesOutcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD ProphylaxisInhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin LymphomaInvasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agentsImpact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphomaVenetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemiaAssociation between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell TransplantationAssociation of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemiaHypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for useLong-term Outcomes of Allogeneic Hematopoietic Cell transplantation with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as GVHD prophylaxis in Patients with Acute Lymphoblastic Leukemia
P50
Q36557015-321E2B40-08E9-4212-9DE6-A6B07C39575EQ38164572-28CD1063-63C1-4851-8E02-F4DCB2F3994BQ38667361-D63CC1E4-A74F-4214-B017-9811AB547BF1Q38769054-03068969-A056-4292-994A-016C84FBC487Q38942311-994B3E19-00B0-41D4-B96D-E28FFAEE51FEQ40368411-8E08DB91-1CD1-4E79-A996-DCF71A0EF63DQ47562175-4551A806-2D51-40E2-9988-7CDF58BE4BFBQ47562930-2EADCA03-1921-458F-A8A3-2598F499BC9EQ52592341-B4747D61-383C-4EE3-B1B5-AC80521B80FBQ54213853-14D101D7-1CBC-46EF-B8CE-5CAD3A46E37EQ58776910-04ABCB1A-6E36-43A4-88D3-49E6D5019C61Q58793885-3A9995C9-59EF-4A95-ABF6-1F7F6B992D9BQ60915295-E015F379-608D-43F1-99C9-1D1E10E533F4Q64974375-2D5D85CC-5B65-46F6-B114-54AD1ECFEADDQ87515207-019CDB89-BC9D-4032-B8E3-62EE5D7552ADQ89607368-14985029-99C1-4399-A4F6-05FFC377E115Q89676037-472A83DF-BAE8-48D9-82EC-E5F20787B673Q90179896-F403CBE5-35B8-4A02-83B6-AF57CF0C2C2DQ90365499-F36B7EB5-9AF8-474D-AE82-9C0E6202F62CQ90565944-30CDBE5A-A5F4-48DE-A16A-8F35A5425DD1Q91152135-F80DD870-2DCD-4449-8344-3110328083C2Q91306195-95F19061-6297-4304-B294-6BBE8797E5C2Q91509508-2F9F339A-AB2F-4342-9ECF-0A2ACAF7029BQ91766566-B32DBB2D-3143-4860-81B3-D0B07ED515D6Q91801392-6D711591-0F9B-4C7C-A501-FEF8921CBBFCQ92110937-F162BC8D-B16F-4085-81F9-9B04E1DC6659Q92806132-095C3883-5200-40C9-BF0A-2C8C3EA6AE15Q92839731-BCEE7DF1-6CA8-4EF6-8101-3858B1293D23Q93153887-F1357549-D973-4B4A-A50B-5E58F226DDF3Q93382063-EEC08818-B229-40E8-80BC-3E669E4E1EE0Q94951005-A920C118-7634-4F77-B689-ECCC8F7ACE89
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Matthew Mei
@ast
Matthew Mei
@en
Matthew Mei
@es
Matthew Mei
@nl
Matthew Mei
@sl
type
label
Matthew Mei
@ast
Matthew Mei
@en
Matthew Mei
@es
Matthew Mei
@nl
Matthew Mei
@sl
prefLabel
Matthew Mei
@ast
Matthew Mei
@en
Matthew Mei
@es
Matthew Mei
@nl
Matthew Mei
@sl
P106
P31
P496
0000-0002-1109-6955